(lp0
S"Horizon Pharma plc to Host First-Quarter 2017 Conference Call and Webcast on ... Yahoo Finance - Apr 13, 2017 DUBLIN, Ireland, April 13, 2017  -- Horizon Pharma plc , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that&nbsp;...Horizon Pharma plc declined in the Previous Trading Session with the Change of ... - Free ObserverDimensional Fund Advisors LP Has $41.933 Million Position in Horizon Pharma ... - Sports Perspectives"
p1
aS"Horizon Pharma plc Announces &quot;UCD in Common&quot; for the Urea Cycle Disorder (UCD ... GlobeNewswire  - Mar 16, 2017 DUBLIN, Ireland, March 16, 2017  -- Horizon Pharma plc , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible&nbsp;..."
p2
aS"Horizon Pharma plc Named to the Crain's Chicago Business 2017 Best Places To ... Yahoo Finance - Apr 7, 2017 DUBLIN, Ireland, April 07, 2017  -- Horizon Pharma plc , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that&nbsp;..."
p3
aS"Horizon Pharma plc Launches RAREis Campaign Elevating Faces of the Rare ... GlobeNewswire  - Feb 28, 2017 DUBLIN, Ireland, Feb. 28, 2017  -- Horizon Pharma plc , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible&nbsp;...Horizon Pharma  Misses Q4 Earnings &amp; Revenues - Yahoo FinanceHorizon Pharma's  CEO Timothy Walbert on Q4 2016 Results - Earnings Call ... - Seeking Alpha"
p4
aS"Horizon Pharma plc Announces Urea Cycle Disorders Medical Foods and ... GlobeNewswire  - Mar 2, 2017 DUBLIN, Ireland, March 02, 2017  -- Horizon Pharma plc , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible&nbsp;..."
p5
aS"Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp. GlobeNewswire  - Oct 25, 2016 DUBLIN, Ireland, Oct. 25, 2016  -- Horizon Pharma plc  a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible&nbsp;...Horizon Pharma  Stock: Spikes On Raptor Acquisition, Fortifies Pipeline ... - CNA Finance "
p6
aS'Horizon Pharma plc  to Acquire Raptor Pharmaceutical  for $800M StreetInsider.com - Sep 12, 2016 Horizon Pharma plc  and Raptor Pharmaceutical Corp.  announced the companies have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Raptor&nbsp;...Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in ... - GlobeNewswire Horizon Pharma to buy Raptor Pharma for $800 mln - Reuters UK'
p7
aS'Global Genes and Horizon Pharma plc Partner to Offer Nephropathic Cystinosis ... PR Newswire  - Jan 17, 2017 17, 2017 /PRNewswire-USNewswire/ -- Global Genes and Horizon Pharma plc  announced the Horizon Nephropathic Cystinosis Scholarship , an exclusive opportunity for people living with nephropathic cystinosis to further their&nbsp;...Rare Disease College Report: Nephropathic Cystinosis Scholarships Available - Rare Disease Report'
p8
aS'Horizon Pharma PLC  Given New $30.00 Price Target at Piper Jaffray Companies The Cerbat Gem - 3 hours ago Horizon Pharma PLC logo Horizon Pharma PLC  had its price target decreased by Piper Jaffray Companies from $32.00 to $30.00 in a research note issued to investors on Friday.Horizon Pharma PLC  Stake Increased by Graybill Bartz &amp; Assoc Ltd. - Markets DailyHot Stock Overview: Horizon Pharma plc  - HugoPress'
p9
aS"Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and ... GlobeNewswire  - Oct 13, 2016 DUBLIN, Ireland , Oct. 13, 2016  -- Horizon Pharma plc  , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and&nbsp;..."
p10
a.